Tirzepatide has been used in real world conditions globally since 2022 and in South Africa since December 2024. The safety profile is by now well characterised. Most side effects are gastrointestinal, predictable, and manageable. A smaller number are uncommon but serious enough to be aware of. This page is an honest review.
What Is Common
The following affect a majority of patients at some point, particularly in the first month and after dose increases:
Gastrointestinal
- Nausea. The most common. Mild to moderate for most. Often described as queasy fullness rather than sharp nausea.
- Vomiting. Less common than nausea but does happen, particularly after large or fatty meals.
- Diarrhoea or constipation. Either can occur. Both usually settle within weeks.
- Reflux and indigestion. From slowed gastric emptying. Eating smaller meals reduces this substantially.
- Abdominal discomfort. Mild to moderate. Severe persistent pain is a different concern (see below).
- Reduced appetite. Intended effect. Some people find it more dramatic than expected.
- Belching, bloating, gas. Common and usually mild.
Other common effects
- Fatigue, particularly in the first month
- Headache
- Dizziness, often related to mild dehydration from gastrointestinal losses
- Injection site reactions (redness, itching, small bruise)
- Hair shedding (telogen effluvium, related to weight loss)
- Reduced taste sensitivity
- Dry mouth
Managing The Common Effects
Most patients manage with small adjustments:
- Smaller meals, eaten slowly
- Stop eating when comfortable, not full
- Reduce fatty, greasy, or rich food in the first day or two after each injection
- Stay hydrated, including electrolytes if vomiting or diarrhoea
- Plain, easy to digest food on injection day
- Ginger or peppermint tea help some people with nausea
- Light walks rather than hard exercise in the first week or two
What Is Less Common But Serious
Gallbladder problems
Increased risk of gallstones and gallbladder inflammation, particularly during significant weight loss. Symptoms include upper right abdominal pain (often worse after fatty meals), nausea, and sometimes yellowing of the skin.
Acute kidney injury
Usually secondary to dehydration from severe vomiting or diarrhoea. Maintaining hydration is protective. Pre-existing kidney disease needs monitoring.
Severe allergic reaction
Rare. Difficulty breathing, swelling of face or throat, severe rash. Medical emergency.
Mental health changes
Postmarketing reports have noted depression and suicidal ideation in some patients on GLP-1 medications. Causality is uncertain. People with significant mental health history should discuss this with the prescribing doctor before starting.
Diabetic retinopathy worsening
In people with type 2 diabetes and existing eye disease, rapid glucose improvement can occasionally worsen retinopathy. Baseline eye assessment before starting is recommended for people with known retinopathy.
Thyroid C-cell tumours
Observed in rat studies at high doses. Relevance to humans unclear. As a precaution, the medication is contraindicated in people with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Get An Honest Assessment
An online consultation reviews your medical history including the conditions that make the medication unsafe for some people.
Start ConsultationWhen To Call A Doctor Sooner
Most side effects can be managed at home. Call sooner rather than later if you experience:
- Severe persistent abdominal pain, particularly radiating to the back
- Repeated vomiting and inability to keep fluids down for more than 24 hours
- Signs of dehydration (very dark urine, dizziness on standing, confusion)
- Severe diarrhoea lasting more than a few days
- Yellowing of the skin or whites of the eyes
- Severe upper right abdominal pain (gallbladder)
- Significant rash, swelling, or breathing difficulty
- Significant new low mood or thoughts of self harm
Drug Interactions
Oral contraceptives
Reduced absorption. Backup contraception (barrier method) for four weeks after starting and after each dose increase. Or switch to a non-oral method.
Insulin and sulfonylureas
Hypoglycaemia risk in combination. The dose of insulin or sulfonylurea is usually reduced when tirzepatide is added.
Other oral medications
Slowed gastric emptying can affect absorption. Mostly not clinically significant, but narrow therapeutic index drugs (warfarin, levothyroxine, some seizure medications) may need closer monitoring.
Alcohol
Not a direct interaction. Heavy drinking increases nausea, dehydration, and pancreatitis risk. Many people find tolerance for alcohol decreases on tirzepatide.
Frequently Asked
Nausea, particularly in the first month and after each dose increase. Most people experience some nausea. Most find it manageable with simple eating adjustments. It usually settles within weeks.
It is a rare but recognised risk. Severe persistent abdominal pain, often radiating to the back, warrants urgent assessment and stopping the medication until investigated.
Some hair shedding is reported, but it is generally related to significant weight loss (telogen effluvium) rather than a direct medication effect. It is temporary and resolves as weight stabilises.
Animal studies in rats showed C-cell tumours at high doses. The relevance to humans is unclear. The medication is contraindicated in people with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.